title: Interaction of retinoic acid and interferon in renal cancer cell lines.
abstract: Retinoic acid (RA) can potentiate the antitumor effect of interferons (IFN) in a variety of tumor types, including renal cell carcinoma (RCC). The mechanisms by which RA and IFN increase the antitumor effects in RCC are unknown. We used growth assays and mobility shift assays to examine the effects of combining 13-cis-retinoic acid (CRA) and IFN-alpha (plus IFN-gamma) on proliferation and on the expression of the IFN-specific transcription factor IFN-stimulated gene factor 3 (ISGF3) in RCC cell lines. Combining CRA and IFN-alpha resulted in a significant increase in growth inhibition in four cell lines compared with IFN-alpha or CRA alone. Binding of nuclear extracts from RCC cells to an IFN-stimulated response element (ISRE) oligonucleotide probe following incubation with IFN-alpha was not increased by CRA but was significantly increased by pretreatment by IFN-gamma in a time-dependent fashion. Proliferation assays showed that sequential addition of IFN-gamma and IFN-alpha significantly increased growth inhibition. IFN-alpha but not IFN-gamma or CRA increased the cellular levels Stat2 and p48 but not Statl. IFN-gamma pretreatment enhanced the upregulation of p48 levels by IFN-alpha. Combining RA and IFN results in additive growth inhibition on RCC cell lines. This increase in growth inhibition is not mediated by increased ISGF3 expression.
authors.affiliation: Department of Urology, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA. dnanus@med.cornell.edu
authors.forename: D M
authors.initials: DM
authors.lastname: Nanus
authors.forename: Y
authors.initials: Y
authors.lastname: Geng
authors.forename: R
authors.initials: R
authors.lastname: Shen
authors.forename: H K
authors.initials: HK
authors.lastname: Lai
authors.forename: S R
authors.initials: SR
authors.lastname: Pfeffer
authors.forename: L M
authors.initials: LM
authors.lastname: Pfeffer
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D004347:Drug Interactions; D004357:Drug Synergism; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology; D015474:Isotretinoin / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D014212:Tretinoin; D007371:Interferon-gamma; D015474:Isotretinoin